Medifast, Inc.

MED

$12.56

+0.12%

2026-09-04 12:09:20 EDT+$0.02

Consumer Cyclical

Personal Products & Services

NYSE

Active Trading

Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight ...

Price Action of MED

$12.56

+0.12%+$0.02

High—

Low—

52W High-14.4%

Rel. vol—

Interval

Range4h

Volume—SMA5SMA10

—

Medifast, Inc. (NYSE: MED) is a leading manufacturer and distributor of clinically proven healthy living products and programs, operating through its subsidiary OPTAVIA. The company is recognized as one of the fastest-growing health and wellness communities, providing scientifically developed products, clinically supported plans, and the guidance of independent OPTAVIA Coaches ...Medifast, Inc. (NYSE: MED) is a leading manufacturer and distributor of clinically proven healthy living products and programs, operating through its subsidiary OPTAVIA. The company is recognized as one of the fastest-growing health and wellness communities, providing scientifically developed products, clinically supported plans, and the guidance of independent OPTAVIA Coaches to help customers achieve lifelong transformation. Medifast's product portfolio includes a wide range of consumable items such as snack bars, shakes, smoothies, cereals, soups, and meal replacements, marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. These products are distributed across the United States and the Asia-Pacific region, primarily through direct e-commerce channels, multi-level marketing, and telemarketing. Financially, Medifast has demonstrated significant operational scale with an annualized revenue of approximately $317 million and a market capitalization of roughly $134 million. The company maintains a strong gross profit margin of 69.2% and a current ratio of 4.86, indicating robust liquidity. Despite recent challenges, as reflected in negative profitability metrics over the trailing twelve months, Medifast continues to invest in product innovation, with research and development expenses supporting the introduction of new fortified meal replacements. The company employs 380 full-time staff and is led by CEO Nicholas Johnson, who was appointed in 2026, succeeding Dan Chard, who remains Chairman. Medifast is committed to social responsibility, including charitable efforts to end child hunger through partnerships like No Kid Hungry. With over 40 years of history, Medifast continues to pursue its mission of empowering individuals to adopt healthy habits, aiming to drive long-term value for customers, coaches, and shareholders alike.ExpandCollapse

Founded

1980

Employees

380

CEO

Nicholas Johnson

Full Name

Medifast, Inc.

Sector

Consumer Cyclical

Industry

Personal Products & Services

ROE

-12.68%

Market Cap

$0.14B

Current Ratio

4.86

WACC

7.34%

ROIC

-12.03%

Contact Information

https://medifastinc.com

410 581 8042

1501 S. Clinton Street, Baltimore, MD 21224

Key Metrics of MED

Snapshot

Latest / TTM · 6 periods

Market Cap

$140.37M

ROCE

-7.9%

EV / EBITDA

-26.64x

-1.3% YoY

FCF Yield

2.9%

+1.8% YoY

Cash Conversion Cycle

-57.0d

Current Ratio

4.86

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of MED

Profitability trend

Latest / TTM · 6 periods

Gross Margin

69.2%

Net Margin

-8.1%

P/E Ratio

-5.38x

n/a

Debt / Equity

0.14

n/a

Current Ratio

4.86

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of MED

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.35 · Revenue $71.30M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.12 · Revenue $64.10M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.15 · Revenue $287.70M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.15 · Revenue $70.10M · 1 analysts

Recent history

Aug 3, 2026
Q2 FY2026 · Results reported
EPS $-0.28 · Revenue $76.38M
View filing
May 4, 2026
Q1 FY2026 · Results reported
EPS $-0.19 · Revenue $76.04M
View filing
Feb 17, 2026
FY2025 · Annual results
EPS $-1.70 · Revenue $385.79M
View filing
Nov 3, 2025
Q3 FY2025 · Results reported
EPS $-0.21 · Revenue $89.41M
View filing
Aug 4, 2025
Q2 FY2025 · Results reported
EPS $0.22 · Revenue $105.56M
View filing
Apr 28, 2025
Q1 FY2025 · Results reported
EPS $-0.07 · Revenue $115.73M
View filing

Financial Statements of MED

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$385.8M	-36.0%	+0.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-18.7M	-993.0%	-46.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+71.3%	-3.3%	+2.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-3.7%	-871.2%	-293.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-4.8%	-1494.5%	-45.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$1.2M	-92.7%	+187.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+0.3%	-88.5%	+186.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	8.4%	+9.9%	+72.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	4.69x	+40.5%	+1.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$257.0M	-9.6%	+3.3%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.70 vs -1.12	-51.8%	-0.28 vs -0.65	+56.9%
Revenue Surprise	$385.8M vs $382.1M	+1.0%	$76.4M vs $72.7M	+5.1%

Insider Transactions of MED

Acquisitions (A)

Since May 26, 2026

Disposals (D)

Since May 26, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 26, 2026	Kiai Parsa	director	Common Stock	A	41,975	$12.26
Aug 26, 2026	Kiai Parsa	director	Common Stock	A	1,175	$12.26
Aug 24, 2026	Kiai Parsa	director	Common Stock	A	4,211	$12.00
Aug 24, 2026	Kiai Parsa	director	Common Stock	A	118	$12.00
Aug 20, 2026	Kiai Parsa	director	Common Stock	A	41,975	$11.60

Earnings Call Transcript of MED

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Greetings, and welcome to the Medifast Second Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steven Zenker, Vice President, Investor Relations. Thank you, sir. You may begin. Steven Zenker: Good afternoon, and welcome to Medifast's Second Quarter 2026 Earnings Conference Call. On the call with me today are Nick Johnson, Chief Executive Officer; and Jim Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the second quarter ended June 30, 2026, that went out this afternoon at approximately 4:05 p.m. Eastern Time. If you have not received the release, it is available on the Investor Relations portion of Medifast's website at www.medifastinc.com. This call is being webcast and a replay will also be available on the company's website. Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, and other similar expressions generally identify forward-looking statements. These statements do not guarantee future performance and therefore undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today's release or call. Now I would like to turn the call over to Medifast's Chief Executive Officer, Nick Johnson. Nicholas Johnson: Thanks, Steve, and good afternoon, everyone. It's an honor to be addressing you today in my first earnings call as the CEO of Medifast, and I'm looking forward to conversations with investors over the months and years ahead. In our second quarter, we continued to see positive indicators in our business, maintaining a trend that began in late 2025. Most notably, revenue has stabilized sequentially over the recent quarters, aided by higher coach productivity, which grew for the third consecutive quarter. This is a key metric for us as positive trends historically have preceded revenue and profitability growth. Improved coach productivity is also reflected in the growing percentage of active earning coaches reaching Executive Director rank as our field embraces our strategic transition to metabolic health. We anticipate that these positive trends will continue through the remainder of the year, supported by the launch of our new consumer brand, Trilivy. Trilivy is the first step in our 3.0 strategy, which is the biggest shift for Medifast since we launched OPTAVIA in 2017. The strategy is defined by a 10-year roadmap that will allow us to expand our offer to coaches and clients in the context of a comprehensive metabolic …

Leadership Team of MED

5 executives

Name	Title	Compensation	Gender	Year Born	Status
James Maloney	Chief Financial Officer	USD 727,968	Male	1968	Active
Nicholas Johnson	CEO & President	USD 610,455	Male	1980	Active
Steven Zenker	Vice President of Investor Relations	—	Male	—	Active
Claudia C. Greninger	Chief Human Resources Officer	—	Female	1974	Active
Jonathan Barrett MacKenzie	Vice President of Finance & Chief Accounting Officer	—	Male	1972	Active

Recent News of MED

Zacks Investment Research8/12/2026Neutral

Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?

MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.

Zacks Investment Research8/7/2026Neutral

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

Zacks Investment Research8/7/2026Neutral

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.

Zacks Investment Research8/7/2026Neutral

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Seeking Alpha8/5/2026Neutral

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)

Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.

Historical Employee Count of MED

Current

380

Change

-24.60%

Minimum

380

Maximum

984

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	380	10-K	Feb 17, 2026	View
Dec 31, 2024	504	10-K	Feb 18, 2025	View
Dec 31, 2023	634	10-K	Feb 20, 2024	View
Dec 31, 2022	874	10-K	Feb 21, 2023	View
Dec 31, 2021	984	10-K	Feb 23, 2022	View

Related stocksSpecialty Business Services

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Medifast, Inc.